Scott Gottlieb notes the chilling effect of current DOJ policy. I still think he underestimates the incentives facing prosecutors and pharmaceutical companies in hoping for internal reform or successful pharmaceutical-company challenges; reform is going to have to come from the legislature or from higher up in the executive branch, and neither is likely in this administration or in a media environment that views pharmaceutical companies as evils to be barely tolerated rather than the major driver of healthcare innovation.
More on Caronia
- Bond v. U.S.
- A Poster Child for Overcriminalization: The History of the Lacey Act
- Opposing FCPA Overcriminalization
- The Detrimental Effects of Extreme Deterrence
- The FDA Strikes Again: Its ban on home testing kits is, as usual, likely to do more harm than good
- In the Matter of McCutcheon: The Merits of Campaign-Finance "Aggregation"
- Debate Concludes: The need for a reasonable mistake of law defense
- Reply: Never underestimate a defense lawyer's imagination
- A Debate: The need for a reasonable mistake of law defense
- Follow the debate: Overcriminalization is a problem, but a 'mistake of law defense' is not the right solution
- New Featured Discussion: Reconsidering the 'mistake of law defense' in the battle against overcriminalization
- Teen Sexting, Youthful Mistake or Felony?
- New Podcast: Federal overcriminalization hurts Ohioans
- Illinois, Chicago treats small businesses like they're a problem
- A better solution to prison overcrowding
Center for Legal Policy at the